Facebook Linkedin RSS Twitter Youtube
Home 2023

Health care investment

StockWatch: Biogen’s New CEO Takes Slow Approach to New Cost Cuts
Cancer

StockWatch: Biogen’s New CEO Takes Slow Approach to New Cost Cuts

Inside VC: Samir Kaul of Khosla Ventures on Evaluating and Managing Risk in 2023
Artificial Intelligence

Inside VC: Samir Kaul of Khosla Ventures on Evaluating and Managing Risk in 2023

EY Eyes Comeback for Biopharma M&A
GEN Edge

EY Eyes Comeback for Biopharma M&A

Sanofi Extends Deal with CytoReason to License IBD Disease Modeling
Drug Discovery

Sanofi Extends Deal with CytoReason to License IBD Disease Modeling

A16z’s Vijay Pande: Why Gene Editing Will Soon Be “Off to the Races”
Artificial Intelligence

A16z’s Vijay Pande: Why Gene Editing Will Soon Be “Off to the Races”

Engineering Biology: a16z’s Vijay Pande Discusses Shift from Bespoke Drugs
Artificial Intelligence

Engineering Biology: a16z’s Vijay Pande Discusses Shift from Bespoke Drugs

Arbor and Vertex to Advance Reverse Transcriptase Genetic Medicines
GEN Edge

Arbor and Vertex to Advance Reverse Transcriptase Genetic Medicines

AbbVie to Develop mRNA Modulators Using Anima Biotech Platform
Drug Discovery

AbbVie to Develop mRNA Modulators Using Anima Biotech Platform

Agilent Investing $725 Million to Expand Manufacturing Capacity for Nucleic Acid-Based Therapeutic Production
Bioprocessing

Agilent Investing $725 Million to Expand Manufacturing Capacity for Nucleic Acid-Based Therapeutic Production

Bruker Makes Majority-Ownership Investment in Biognosys and Forms Proteomics CRO Partnership
Drug Discovery

Bruker Makes Majority-Ownership Investment in Biognosys and Forms Proteomics CRO Partnership

123...28Page 2 of 28
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.